GBA Presents: House of Gummy-!

A HA! 2)


RBC Capital Markets started coverage of Jasper Therapeutics (NASDAQ:JSPR) with an outperform rating, citing the company's potential to access the $100B+ mast cell disease market.7 mins ago

On Thursday, RBC Capital initiated coverage on Jasper Therapeutics (NASDAQ:JSPR), assigning an Outperform rating and setting a price target of $70.00.

The firm's assessment is based on the potential of Jasper's leading asset, briquilimab, which they believe could significantly impact the mast cell disease market, valued at over $100 billion.

Briquilimab, an anti-c-Kit monoclonal antibody, is being developed primarily for urticaria treatments, with the market for these treatments expected to reach $1.6 billion in peak sales. RBC Capital's valuation hinges on the drug's advantages, which include a faster response time, less frequent dosing, and a favorable safety profile due to its ability to deeply and rapidly deplete mast cells.

RBC Capital anticipates that clinical updates expected in the third quarter of 2024 for chronic spontaneous urticaria (CSU) and the second half of 2024 for chronic inducible urticaria (CIndU) will serve as initial validation points and provide near-term catalysts for the stock.
 
a ha 3

Let's get Fancy!!!!!

Royal Bank of Canada Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR

Equities research analysts at Royal Bank of Canada began coverage on shares ofJasper Therapeutics (NASDAQ:JSPR-Get Free Gummy)in a research note issued on Thursday, The brokerage set an "outperform" rating and a $70.00 price target on the stock. Royal Bank of Canada's price objective points to a potential upside of 133.88% from the company's previous close.

JSPR has been the subject of a number of other reports. TD Cowen assumed coverage on shares of Jasper Therapeutics in a research report on Monday, March 18th. They issued an "outperform" rating for the company. Oppenheimer restated an "outperform" rating and set a $80.00 target price on shares of Jasper Therapeutics in a research report on Thursday, March 7th.
 
Ok this is all very recent. Stk has not moved yet we have insider buying i think we are onto something.

IMMEDIATE BUY!!!!!!!--- I'M IN CT../// SHIT.

I THINK I CAN HF THIS! THEY SEME LEGIT ENOUGH.......

WHOOP WHOOP WHOOP THIS IS HOW YOU RESEARCH-!

 
We have had a bunch of home run in the biotech space as usual but I have not been chasing waiting for an idea to surface that may be half as good as Viking. I believE tonight we Have fouNd that name--JASPER
 
I can't believe we came up with another idea on page 1549.

When will this end?... If Van has started posting on other threads then we know this one has gone on to long. It is so hard to stop though-- the children.

Since we called the Oct low a week before it happened we have steadfastly held to one thought process-- the 1st rate cut is the time to put $'s aside. I came up with that reading old trends on the market. It usually happens though due to a struggling economy that is causing said rate cut and that is not the case this time-- or is it? Throw in a Trump wild card and the 1st cut is the cue to EXIT some portion of the trade.

THAT WOULD SEEM AN APPROPRIATE TIME TO END THIS THREAD....

 
$1.37 WAS THE HOD DAY TODAY RAN INTO SOME TROUBLE. HOPEFULY THEY GET A BUYOUT OFFER OVER THE WEEKEND. (Watch Them File For Bankruptcy!)

LLAP Terran Orbital Corporation

$1.31 0.05(+3.97%)4:00 PM 03/28/24
NYSE |$USD |Post-Market:$1.30-0.01(-0.76%)4:28 PM

HAVE YOU HAD YOUR FILL OF GUMMY TODAY-?
AMERICA'S #1 STOCK THREAD-!!

 
Tell you all a funny story. Funny/sad. This morning i was making the bed and and I heard over the radio that Mayor Adams was having abig reveal press conference about stopping guns in the subway.

I knew immediately what that meant walk free scanners a la->EVLV. I said to my wife bet you he buys a bunch of EVLV...

Then the HF calls and I tell this jr watch EVLV...

Did I buy the stock. No. I was to busy leaving for ct....

Last I heard up 22% :mad:
 
You must log in or register to reply here.
Back
Top